BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22

• The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene therapy, valoctocogene roxaparvovec.

• With today's validation, the application review can now commence. A CHMP opinion is anticipated in the first half of 2022.

• BioMarin resubmitted the European marketing application in June.

• In the U.S., BioMarin intends to submit two-year follow-up safety and efficacy data on all study participants from the Phase 3 GENEr8-1 study to support the benefit/risk assessment of valoctocogene roxaparvovec, as previously requested by the FDA.

• BioMarin targets an application resubmission in Q2 of 2022, assuming favorable study results, followed by an expected six-month review by the FDA.

• Price Action: BMRN shares are down 1.21% at $78.72 during the market session on the last check Thursday.

• Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

• Click here for options trades from Benzinga

• IMV Stock Plunges After Raising M Via Equity Issued At 16% Discount

• NLS Pharma Stock Gains As Its Narcolepsy Candidate To Enter Mid-Stage Study Next Month

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.